Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy

Clinical Therapeutics

Volumn 26, Issue 11, 2004, Pages 1714-1727

  Bell, David S H ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

combination therapy; dosing; glimepiride; secretagogue; sulfonylurea; type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; CHLORPROPAMIDE; CRINASE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE;

ASTHENIA; BLOOD TOXICITY; CLINICAL TRIAL; DIABETES MELLITUS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPOGLYCEMIA; MEDICAL LITERATURE; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SKIN TOXICITY; UNITED STATES; WEIGHT GAIN;

EID: 11844278320     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.10.014     Document Type: Article

References (60)

1. Centers for Disease Control and Prevention National Diabetes Fact Sheet General Information and National Estimates on Diabetes in the United States, 2003 Rev ed. 2004 US Dept of Health and Human Services, Centers for Disease Control and Prevention Atlanta, Ga
2. Available at: Centers for Disease Control and Prevention Data & trends: Diabetes surveillance system - prevalence of diabetes Accessed June 8, 2004
3. Available at: Centers for Disease Control and Prevention Data & trends: Diabetes surveillance system - insulin and oral medication use Accessed June 8 2004
4. American Association of Clinical Endocrinologists Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self- management - 2002 update Endocr Pract 8 Suppl 1 2002 41 82
5. Standards of medical care in diabetes Diabetes Care 27 Suppl 1 2004 S15 S35
6. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review JAMA 287 2002 360 372
7. OAD Market NRxs and TRxs (with Shares) 2004 Verispan Yardley, Pa
8. Bell D.S. Secretagogues and cardiac risk Endocrinologist 14 2004 33 37
9. Buren J., Lindmark S., Renstrom F., and Eriksson J.W. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: Is cellular insulin resistance caused byglucotoxicity in vivo? Metabolism 52 2003 239 245
10. Kaiser N., Lebowitz G., and Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus J Pediatr Endocrinol Metab 16 2003 5 22
11. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 131 1999 281 303
12. Abstract Garber A., Sankoh S., Mohideen P., and Bruce S. Glyburide/metformin tablets versus metformin plus rosightazone in type 2 diabetes patients uncontrolled on metformin: Attaining glycemic goals Diabetes 52 Suppl 1 2003 A119 A120
13. Bell D.S., and Ovalle E. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea? Endocr Pract 6 2000 293 295
14. Turner R.C., Cull C.A., Frighi V., Holman R.R. UK Prospective Diabetes Study (UKPDS) Group Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multipletherapies (UKPDS 49) JAMA 281 1999 2005 2012
15. Lebovitz H.E. Insulin secretagogues: Old and new Diabetes Rev 7 1999 139 153
16. June Clark C.M. Jr, and Goldberg R.B. Glimepiride dosing and efficacy: Results of placebo-controlled, dose-regimen, and active-controlled trials Postgrad Med Special Rep 1997 45 46
17. Dills D.G., Schneider J. Glimepiride/Glyburide Research Group Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study Horm Metab Res 28 1996 426 429
18. Draeger K.E., Wemicke-Panten K., and Lomp H.J. Longterm treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): A doubleblind comparison with glibenclamide Horm Metab Res 28 1996 419 425
19. Amaryl [package insert] 2003 Aventis Pharmaceuticals Inc Bridgewater, NJ
20. Diaßeta [prescribing information] 2003 Aventis Pharmaceuticals Inc Bridgewater, NJ
21. Glucotrol [prescribing information] 2000 Pfizer Inc New York, NY
22. GlucotrolXL [prescribing information] 2001 Pfizer Inc New York, NY
23. Micronase [prescribing information] 2002 Pharmacia & Upjohn Company Kalamazoo, MI
24. Holstein A., Plaschke A., and Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide Diabetes Metab Res Rev 17 2001 467 473
25. Schneider J. An overview of the safety and tolerance of glimepiride Horm Metab Res 28 1996 413 418
26. United Kingdom Prospective Diabetes Study Group United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy Ann Intern Med 128 1998 165 175
27. [published correction appears in Lancet. 1999;354:602] UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 33) Lancet 352 1998 837 853
28. Luis Bautista J., Bugos C., Dimberger G., and Atherton T. Efficacy and safety profile of glimepiride in Mexican American patients with type 2 diabetes mellitus: A ran domized, placebo-controlled study Clin Ther 25 2003 194 209
29. Martin S., Kolb H., and Beuth J. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: A multicentre retrospective cohort study Diabetologia 46 2003 1611 1617
30. Abstract Bugos C., Austin M., Atherton T., and Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: A meta-analysis Diabetes Res Clin Pract 50 Suppl 1 2000 547
31. Abstract Ito T., Morita H., and Kawai K. Glimepiride has antihyperglycemic effects without increasing body weight in patients with type 2 diabetes in Japan Diabetes 53 Suppl 2 2004 A477
32. Scholz G.H., Schneider K., Knirsch W., and Becker G. Efficacy and tolerability of glimepiride in daily practice: A noninterventional observational cohort study Clin Drug Invest 21 2001 597 604
33. 1c and body weight in type 2 diabetes: Results of a 1.5-year follow-up study Diabetes Res Clin Pract 61 2003 13 19
34. Cefalu W.T., Schneider D.J., and Carlson H.E. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects Diabetes Care 25 2002 2123 2128
35. Simonson D.C., Kourides I.A., Feinglos M. Glipizide Gastrointestinal Therapeutic System Study Group Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion inNIDDM. Results of two multicentre, randomized, placebo-controlled clinical trials Diabetes Care 20 1997 597 606
36. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium Circulation 74 1986 1124 1136
37. Yellon D.M., Baxter G.F., and Mather M.S. Angina reassessed: Pain or protector? Lancet 347 1996 1159 1162
38. Garratt K.N., Brady P.A., and Hassinger N.L. Sulfonylurea dings increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardiol 33 1999 119 124
39. Hadden D.R., Montgomery D.A., and Weaver J.A. Myocardial infarction in maturity-onset diabetics. A retrospective study Lancet 1 1972 335 338
40. Johnson J.A., Majumdar S.R., Simpson S.H., and Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes Diabetes Care 25 2002 2244 2248
41. Johnston P.S., Lebovitz H.E., and Coniff R.F. Advantages of α glucosidase inhibition as monotherapy in elderly type 2 diabetic patients J Clin Endocrinol Metab 83 1998 1515 1522
42. (Suppl) Meinert C.L., Knatterud G.L., Trout T.E., and Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results Diabetes 19 1970 789 830
43. Scognamigho R., Avogam A., and Vigili de Kreutzenberg S. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes Diabetes 51 2002 808 812
44. Lee T.M., and Chou T.E. Impairment of myocardial protection in type 2 diabetic patients J Clin Endocrinol Metab 88 2003 531 537
45. Stenman S., Melander A., Groop P.H., and Groop L.C. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118 1993 169 172
46. Wåhlin-Boll E., Sartor G., Melander A., and Schersten B. Impaired effect of sulfonylurea following increased dosage Eur J Clin Pharmacol 22 1982 21 25
47. Groop L.C., Barzilai N., and Ratheiser K. Dose dependent effects of glyburide on insulin secretion and glucose uptake in humans Diabetes Care 14 1991 724 727
48. Groop L., Groop P.H., and Stenman S. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment Diabetes Care 10 1987 71 78
49. Goldberg R.B., Holvey S.M., Schneider J. Glimepiride Protocol #201 Study Group A dose response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents Diabetes Care 19 1996 849 856
50. Riddle M. Combining sulfonylureas and other oral agents Am J Med 108 Suppl 6A 2000 15S 22S
51. Bell D.S. Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes Endocr Pract 9 2003 98 101
52. Charpentier G., Fleury F., and Kabir M. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients Diabet Med 18 2001 828 834
53. GlaxoSmithKline unveils a broad R&D pipeline of innovative science and class-leading compounds [press release] October 12, 2004
54. Abstract Rosenstock J., Porter L.E., Heise M.A. RESULT Study Group The RESULT Study in older type 2 diabetes: Reaching durable glycemic goals with combination sulfonylurea and rosightazone Diabetes 53 Suppl 2 2004 A160
55. Abstract Weston W.M., Chen T., and Coghlan R.O. Rosightazone added early to sulfonylurea provides superior control vs uptitration of sulfonylurea Diabetes 53 Suppl 2 2004 A151
56. Abstract Herman W., Dirani R., and O'Neill M.C. Reduction in use of health care services with combination sulfonylurea (SU) and rosightazone (RSG): The RESULT trial Diabetes 53 Suppl 2 2004 A128
57. Abstract Herman W., Dirani R., and Suppapanya N. Reduction in use of health care services with combination sulfonylurea (SU) and rosightazone (RSG): Validation of the RESULT trial Diabetes 53 Suppl 2 2004 A128
58. Derosa G., Cicero A.F., and Gaddi A. Metabolic effects of pioglitazone and rosightazone in patients with diabetes and metabolic syndrome treated with glime piride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial Clin Ther 26 2004 744 754
59. Abstract Moules I., Edwards G., and Mariz S. Two-year efficacy of the addition of pioglitazone to sulfonylurea therapy in patients with T2DM Diabetes 53 Suppl 2 2004 A139
60. Abstract Vanderpoel D.R., Hussein M.A., and Watson-Heidari T. Improved adherence with rosiglitazone/metformin fixed-dose combination therapy: A retrospective analysis Diabetes 53 Suppl 2 2004 A481 A482